Dr. Fenniri received all his degrees from the University of Strasbourg, France. After a postdoctoral fellowship at the Scripps Research Institute, CA, USA, he moved to Purdue University, IN, USA, where he established the Purdue Laboratory for Chemical Nanotechnology (1999). In 2003, He joined the National Research Council as a founding member of the National Institute for Nanotechnology and as full professor of chemistry and biomedical engineering at the University of Alberta (Canada, 2003-2013). Dr. Fenniri is currently Professor of Chemical Engineering, Bioengineering, Chemistry & Chemical Biology at Northeastern University, Boston, MA, USA. Dr. Fenniri’s contributions appeared in over 220 peer-reviewed publications, 21 patents and patent applications, and over 500 contributed national and international conference papers. Dr. Fenniri has also lectured extensively around the globe and has been an invited professor at several institutes and universities.
Rebecca Carrier earned a Bachelor’s Degree in Chemical Engineering from Rensselaer Polytechnic Institute (RPI) in Troy, NY, USA, in 1995, and a Doctoral Degree in Chemical Engineering from Massachusetts Institute of Technology in 2000, where she worked in cardiac muscle tissue engineering. After completing her graduate studies, Dr. Carrier worked at Pfizer, Inc., as a Senior Research Scientist in oral controlled release drug delivery for three years. She joined the Northeastern University (NU) Chemical Engineering Department in 2003. The goal of Dr. Carrier’s research program integrates drug delivery and tissue engineering to enable technologies that benefit human health, with efforts mainly focused on the intestine and the retina. To advance research efforts, Dr. Carrier has been awarded grants from the National Institutes of Health (NIH) and National Science Foundation (NSF), and Dr. Carrier has also fostered collaboration and worked closely with multiple industrial partners including Pfizer, Merck, Boehringer Ingelheim, and Simulations Plus, Inc., a leader in development of pharmaceutical modeling software. Dr. Carrier received the National Science Foundation CAREER award in 2008 for mechanistic studies and modeling of lipid based drug delivery systems in the GI tract, the NU “Outstanding Teacher” and “Faculty Fellow” Awards in 2011 and 2014 for excellence in teaching and research leadership, and the Soren Buus Outstanding Research Award in 2017. She was invited to participate in the National Academy of Engineering Frontiers of Engineering (2016) and Frontiers of Engineering Education (2013) Symposia. She served as the Member-At-Large for the Society for Biomaterials from 2018-2019, and was inducted into the American Institute for Medical and Biological Engineering in 2019.
Joined the Chemical Engineering Department in Fall 2013.
The primary focus of our research is to study the means by which endothelial cell mechanotransduction occurs in order to prevent or promote atherosclerosis. We are applying engineering to study the structure and function of the endothelial cell surface glycocalyx that directly interfaces with flowing blood and sheds in the presence of atherosclerosis. We are using cryopreservation (rapid freezing/freeze substitution) and transmission electron microscopy to define the ultrastructure of the endothelial surface glycocalyx and its changes as a result of the macro- or micro-vessel origin and due to the bio-chemical and -mechanical environment. RNA interference techniques, fluorescent intracellular biomarkers, fluorescence confocal microscopy, and protein biochemistry are applied to further clarify the mechanisms by which various flow patterns impact endothelial cell surface glycocalyx ultrastructure, its transduction of fluid forces into biological responses, and its role in vascular health or disease. In vivo studies are performed using high fat fed apolipoprotein E (ApoE) knockout mice, a well-established animal model of atherosclerosis, to determine which glycocalyx components can be targeted to prevent, diagnose, or treat atherosclerosis.
Dr. Martin Kariuki Kimani is an Adjunct Teaching Professor in the M.S Biotechnology PSM programs with a dual appointment in the Department of Chemical Engineering at Northeastern University. He is also an Associate Director within the Manufacturing Sciences and Technology organization at Sarepta Therapeutics. Dr. Kimani received his B.S, M.S and Ph.D degrees in chemical engineering from Northeastern University. During his graduate studies, his research was focused on developing electrochemical sensors for detecting microbial species with an application on pathogenic diagnostics. His research interests include developing biosensors for bioprocess applications.
Over the course of his career, Dr. Kimani has worked in multiple industries that span from consumer products, chemical processing, nanotechnology to biotechnology. During his time at Johnson & Johnson’s consumer products, he worked on formulation development for dry skin therapies. He then worked at the Marcus Hook, PA Sunoco Oil refinery as a process engineer specializing in the Fluidic Catalytic Cracking unit (FCC). At Sunoco, he designed predictive process models for optimizing catalytic performance based on the choice of feedstocks to the FCC system.
He moved on to Abbvie (former Abbott Laboratories) supporting their commercial process engineering team. At Abbvie he worked on scale down chromatography resin packing studies with subsequent implementation at scale to provide reproducible column qualification procedures among other projects.
Dr. Kimani then worked at Sanofi-Genzyme where he held several positions with a focus on commercial process engineering, project management, project engineering and process validation. His latest project was working as the Process Validation Lead in the regulatory approval/licensing of an extensive re-design of the commercial production bioreactors and automated process controls.
Dr. Kimani went on to work as a Process Validation Consultant at Takeda Pharmaceuticals. He is currently an Associate Director within the Manufacturing Sciences and Technology (MSAT) Process Sciences group at Sarepta Therapeutics. Dr Kimani is combining his research interests with his unique bioprocessing experience to further develop biosensors within the biotechnology landscape.
Ph.D., Chemical Engineering, Cornell University
Dissertation: “The Enhancement of the Productivity of Ajmalicine from Immobilized Catharanthus roseus Cell Cultures,”
Advisor: Prof. Michael L. Shuler
B.S., Summa cum laude, Chemical Engineering, University of Kansas
Srinivas Sridhar is University Distinguished Professor of Physics, Biomedical Engineering and Chemical Engineering at Northeastern University, and Lecturer on Radiation Oncology, Harvard Medical School. He is the Director and Principal Investigator of Nanomedicine Academy and the NIH CaNCURE programs, and the founding director of the Nanomedicine Innovation Center, an interdisciplinary center with research and education thrusts in nanomedicine, nanomaterials and neurotechnology. From 2004 to 2008 he served as Vice Provost for Research at Northeastern University, overseeing the University’s research portfolio. An elected Fellow of the American Physical Society, Sridhar’s current areas of research are nanomedicine and neurotechnology. His paper in Nature in 2003 was listed among Breakthroughs of 2003 by the journal Science. He has published more than 200 articles on his work in nanomedicine, neurotechnology, nanophotonics, metamaterials, quantum chaos, superconductivity and collective excitations in materials.